What is the core difference between retatrutide and tirzepatide?
Both molecules are incretin-based metabolic agents from Eli Lilly, but they hit a different number of receptors. Tirzepatide is a dual agonist: it activates the GIP and GLP-1 receptors. Retatrutide is a triple agonist — it adds a third target, the glucagon receptor.
That third arm is the headline. Glucagon-receptor activity is associated with increased energy expenditure and reduced liver fat, which is the mechanistic rationale for why retatrutide produced larger weight-loss figures in early trials. It is also why retatrutide is being studied specifically in metabolic dysfunction-associated steatotic liver disease (MASLD), not just obesity and type 2 diabetes.
The practical difference that matters most today, though, is regulatory: tirzepatide is an approved medicine you can be prescribed, while retatrutide is still an investigational compound being evaluated in clinical trials.
Which produced more weight loss in clinical trials?
In its phase 2 obesity trial, retatrutide at the 12 mg dose produced a mean weight reduction of roughly 24.2% at 48 weeks — among the largest figures reported for any pharmacological agent to date. Tirzepatide, in the larger phase 3 SURMOUNT-1 trial, produced roughly 20.9% at the 15 mg dose over 72 weeks.
It is important not to over-read this. These came from different trials, with different durations, dose-titration schedules, and patient populations — they were not compared head-to-head. A larger phase 2 number does not guarantee superiority once retatrutide completes phase 3, where efficacy figures frequently regress toward the mean as populations broaden.
How do the side effects compare?
The side-effect profiles look broadly similar because both drugs share GLP-1 and GIP activity. The dominant adverse events in both are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and in both they are dose-dependent and tend to ease as the body adapts to gradual dose escalation.
Retatrutide trials also reported dose-dependent increases in heart rate and some transient skin-sensitivity reports; its longer-term safety record is by definition thinner because it has not completed phase 3 or accumulated post-market data the way tirzepatide has. This asymmetry in evidence is itself a meaningful difference.
Is retatrutide available, and is it legal?
Retatrutide is not approved by the FDA or any major regulator. The only lawful way to receive it is enrollment in a clinical trial. Material sold online as "research" retatrutide is explicitly labeled not for human use, is unregulated for identity, purity, and sterility, and falls outside the approved supply chain.
Tirzepatide, by contrast, is available by prescription as Mounjaro or Zepbound through licensed pharmacies. If weight loss or glycemic control is the goal today, tirzepatide is the option with an approval, a known supply chain, and an established safety database. Discuss any GLP-1 decision with a licensed clinician.
Tracking either compound on PeptidePanel
Whichever agent a clinician prescribes, the day-to-day work is the same: log doses, watch the biomarkers that matter (HbA1c, lipids, liver enzymes, weight trend), and catch side effects early. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, or supply any compound. It is a monitoring tool for protocols that a qualified prescriber has put you on.